<DOC>
	<DOCNO>NCT01724112</DOCNO>
	<brief_summary>This study determine efficacy , safety , tolerability 40 milligram ( mg ) once-daily ( QD ) dose LY2940094 8 week participant MDD .</brief_summary>
	<brief_title>Study Efficacy Safety LY2940094 Participants With Major Depressive Disorder ( MDD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Have diagnosis MDD without psychotic feature define Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) Have clinically significant depressive symptom define GRID Hamilton Depression Rating Scale 17 ( HAMD17 ) Total Score ≥20 screen Body mass index ( BMI ) 18 35 kilogram per square meter ( kg/m² ) Have current previous diagnosis bipolar I II disorder , MDD psychotic feature , schizoaffective disorder , schizophrenia , psychotic disorder Currently meeting criterion treatmentresistant depression define ≥2 document , fail treatment trial adequate dose duration register antidepressant current depressive episode Had electroconvulsive treatment , transcranial magnetic stimulation , vagal nerve stimulation symptom depression 6 month prior screen Have clinically significant medical uncontrolled condition circumstance prior randomization could affect participant safety</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>